Unmet Needs and Future Perspective in the Frontline Management of mRCC
Panelists discuss how unmet needs persist in first-line treatment of metastatic renal cell carcinoma, exploring anticipated advances in tyrosine kinase inhibitor–based therapies and other novel approaches that may address these challenges in the coming years.
EP: 1.Evolving First-Line Treatment Strategies in Metastatic RCC: Key Factors Shaping Decision-Making
EP: 2.Translating Clinical Data Into the Practice Setting: Monotherapy and Combination Therapies in Intermediate/Poor-Risk mRCC
EP: 3.Navigating ICI Plus TKI Combinations for First-Line mRCC: Key Factors in Decision-Making
EP: 4.Key Disease Characteristics Influencing the Choice Between ICI + TKI and ICI + ICI Regimens in mRCC
EP: 5.Key Considerations for Adverse Event Management in mRCC: TKI Monotherapy vs ICI + TKI Combinations
EP: 6.Impact of Adjuvant Immunotherapy on First-Line Treatment Decisions for Newly Diagnosed mRCC
EP: 7.Balancing Efficacy Outcomes With Tolerability and Quality of Life in First-Line mRCC Treatment Decisions
EP: 8.Unmet Needs and Future Perspective in the Frontline Management of mRCC
- What unmet needs persist in first-line treatment of metastatic renal cell carcinoma (mRCC)? What advances do you anticipate in tyrosine kinase inhibitor–based therapies or other approaches for mRCC in the coming years?
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Promising Results from Phase 1/2 Trial of NKT2152 for Advanced Kidney Cancer
September 20th 2024NKT2152, a novel oral HIF-2α inhibitor, showed promising results in treating advanced clear cell renal cell carcinoma, with an objective response rate of 20% in all-comers and 26.3% in the dose-escalation population.
Read More
GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC
September 19th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or low-volume favorable-risk metastatic clear cell renal cell carcinoma in the first article of a 2-part series.
Read More
